SCHEMBL2052933

SCHEMBL2052933

O=C(Cn1cc(Nc2ncnc3cc(OCCCN4CCN(CCO)CC4)ccc23)cn1)Nc1cccc(F)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 4/20 0.62
FLT4 P35916 4/20 0.62
FLT3 P36888 3/20 0.62
AURKA O14965 14/20 0.60
KDR P35968 6/20 0.59
EGFR P00533 4/20 0.59
BRAF P15056 2/20 0.59
AURKB Q96GD4 9/20 0.56
PDGFRA P16234 2/20 0.51
FLT1 P17948 2/20 0.51
CDK1 P06493 1/20 0.51
CSK P41240 2/20 0.51
KIT P10721 2/20 0.51
PLK4 O00444 1/20 0.51
CIT O14578 1/20 0.51
MUSK O15146 1/20 0.51
EPHB6 O15197 1/20 0.51
MAP3K7 O43318 1/20 0.51
RIPK2 O43353 1/20 0.51
STK10 O94804 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6026680 0.94 PDGFRB (0.61) PDGFRBFLT4FLT3AURKAKDR
SCHEMBL2053495 0.92 KDR (0.64) PDGFRBFLT4FLT3AURKAKDR
SCHEMBL2049232 0.92 AURKA (0.62) PDGFRBFLT4FLT3AURKAKDR
SCHEMBL5131787 0.92 PDGFRB (0.59) PDGFRBFLT4FLT3AURKAKDR
SCHEMBL3428895 0.91 PDGFRB (0.58) PDGFRBFLT4FLT3AURKAKDR
SCHEMBL2052671 0.89 PDGFRB (0.61) PDGFRBFLT4FLT3AURKAKDR
SCHEMBL6027522 0.89 AURKA (0.57) PDGFRBFLT4FLT3AURKAKDR
SCHEMBL2048809 0.88 FLT4 (0.80) PDGFRBFLT4FLT3AURKAKDR
SCHEMBL2053145 0.88 FLT3 (0.69) PDGFRBFLT4FLT3AURKAKDR
SCHEMBL3432058 0.87 AURKA (0.79) PDGFRBFLT4FLT3AURKAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4709139-B2 2011-06-22 JP claimed
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US claimed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP claimed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US claimed
JP-2006523660-A 2006-10-19 JP claimed
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 EP claimed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO claimed
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US disclosed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP disclosed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US disclosed
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 EP disclosed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270692-A1 Chemical compounds CCNI, MKI67, TP53 PDGFRB 1544/4885FLT4 2898/4885FLT3 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.